- Conditions
- Respiratory Tract Infection
- Interventions
- RSV vaccine, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 1,153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 263
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
- Interventions
- artus Influenza A/B RT-PCR Test
- Device
- Lead sponsor
- QIAGEN Gaithersburg, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
- Interventions
- ALVR106, Placebo
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- 17 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- CodaVax-RSV, Normal Saline
- Biological
- Lead sponsor
- Codagenix, Inc
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Interventions
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Diagnostic Test
- Lead sponsor
- LumiraDx UK Limited
- Industry
- Eligibility
- Not listed
- Enrollment
- 589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more
- Conditions
- Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
- Interventions
- Not listed
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Denver, Colorado + 18 more
- Conditions
- Upper Respiratory Tract Infection
- Interventions
- RSV A2
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 4 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSV Polyclonal Immunoglobulin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Participants
- Interventions
- IVX-A12, Licensed RSV Vaccine
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Rilematovir, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Bakersfield, California + 28 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MEDI ΔM2-2 vaccine, Placebo vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Influenza, Human, Respiratory Syncytial Virus Infections
- Interventions
- Swab
- Diagnostic Test
- Lead sponsor
- LumiraDx UK Limited
- Industry
- Eligibility
- Not listed
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Encinitas, California • Madera, California + 17 more
- Conditions
- Healthy
- Interventions
- IVX-A12, Placebo
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- RSV preF-based Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV-F Particle Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV, Placebo
- Biological · Other
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Redding, California • San Diego, California • The Villages, Florida + 9 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Virazole (Ribavirin) Inhalation Solution
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- RSVpreF 120 µg, RSVpreF 60 µg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more